Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262638 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT01262638 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 177 participants.
The verdict
NCT01262638, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
Interventions
- DRUG Placebo
- DRUG ETC-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262638
The ClinicalTrials.gov registry entry for NCT01262638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01262638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262638 about?
NCT01262638 is a clinical study titled "A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides". This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
What is the current status of trial NCT01262638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2010-12. Estimated completion is 2011-08-23.
What interventions are being tested in trial NCT01262638?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG).
Who is sponsoring clinical trial NCT01262638?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.